Hemophagocytic Syndrome with Febrile Neutropenia after Chemotherapy
نویسندگان
چکیده
منابع مشابه
Garenoxacin Prophylaxis for Febrile Neutropenia after Chemotherapy in Hematological Malignancies
Background: Febrile neutropenia is one of the most serious adverse events in patients with hematological malignancies and chemotherapy. The routine use of fluoroquinolone prophylaxis in patients with hematological malignancies is controversial. Therefore, we prospectively evaluated the efficacy and safety of prophylactic use of garenoxacin for febrile neutropenia. Patients and Methods: Consecut...
متن کاملChemotherapy induced febrile neutropenia: management and prevention.
chemotherapy remains the cornerstone of cancer therapy. In most cases bone marrow suppression represents the doselimiting toxicity of these drugs. Druginduced DNA damage at the level of bone marrow progenitor cells results in a fall in circulating neutrophil count. Patients with neutropenia are at increased risk of infection and sepsis.1 The timing of neutropenia is generally predictable; it ty...
متن کاملChemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy
Chemotherapy-induced neutropenia is a common complication in cancer treatment. In this study, we investigated chemotherapy-induced neutropenia that was recently detected in all patients with gynecologic malignancy. Between January 2009 and December 2011, we examined cases of chemotherapy-induced neutropenia reported in our hospital. We analyzed the incidence and clinical features of chemotherap...
متن کاملFebrile neutropenia with bacterial paronychia
The symptoms of infection can be minimal or absent in patients with febrile neutropenia at first. The focal site of infection, which may be the main cause of a fever or be a complication of neutropenia, can develop as neutrophils increase during the clinical course of febrile neutropenia.
متن کاملFebrile neutropenia in chemotherapy treated small-cell lung cancer patients
BACKGROUND Chemotherapy with platinum agent and etoposide for small-cell lung cancer (SCLC) is supposed to be associated with intermediate risk (10-20%) of febrile neutropenia. Primary prophylaxis with granulocyte colony-stimulating factors (G-CSFs) is not routinely recommended by the treatment guidelines. However, in clinical practice febrile neutropenia is often observed with standard etoposi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Internal Medicine
سال: 2014
ISSN: 0918-2918,1349-7235
DOI: 10.2169/internalmedicine.53.2113